XNAS · Healthcare · Biotechnology
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.81 | -1.71 | -111.11% | $0 | ❌ Miss | +0.17% | +7.59% | — |
| 2026-05-12 | Q1 2026 | -0.69 | -0.67 | +2.90% | $0 | ✅ Beat | +0.10% | -12.40% | -8.32% |
| 2026-03-26 |
| Q4 2025 |
| -0.37 |
| -0.45 |
| -21.62% |
| $0 |
| ❌ Miss |
| +1.79% |
| +4.73% |
| +25.28% |
| 2025-11-06 | Q3 2025 | -0.57 | -0.61 | -7.02% | $0 | ❌ Miss | — | — | — |
Showing last 4 quarters.